Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, has announced strong commercial US progress with implants of the alfapump System having been completed at five leading centres since launch in Q4 2025. One of the leading US liver transplant centres has completed its first two implantations, and both Mount Sinai Hospital in New York and University of Pennsylvania have also implanted multiple patients.
In addition, Dartmouth Hitchcock Medical Center and University Medical Center (UMC) of Southern Nevada have each completed their first implantation. Reflecting the strong interest in alfapump therapy across the US, the Company is actively progressing the hospital approval process to complete implants at a further 20 leading institutions.
Sequana Medical is executing a US commercialisation strategy through its own specialty salesforce targeting the 90 US liver transplant centers that perform more than 90% of liver transplants. The alfapump is the first and only active implantable medical device approved in the US for treating recurrent or refractory ascites due to liver cirrhosis. The device automatically and continuously removes ascites fluid from the abdomen to the bladder, offering patients an alternative to paracentesis procedures.
Martijn Blom, Chief Commercial Officer of Sequana Medical said: “We are excited by the building commercial momentum for alfapump in the United States, including our latest expansion to one of the largest solid organ transplant centres in the US, as well as Dartmouth Hitchcock, New Hampshire’s only Level 1 trauma centre and academic medical centre and University Medical Center of Southern Nevada, which features Nevada’s only Level 1 trauma and transplant centres. This expansion further demonstrates the broadening interest in alfapump’s role in advancing treatment for recurrent or refractory liver ascites, and reflects the strong clinical need for improved care.”
Recurrent or refractory ascites is a severe condition characterised by the accumulation of fluid in the abdomen. The current standard treatment involves therapeutic paracentesis, an invasive and burdensome procedure that drains ascites from the abdomen using a large needle. This procedure often needs to be repeated weekly or monthly, according to Sequana.
Ian Crosbie, Chief Executive Officer of Sequana Medical added: “The medical centres that have already implanted multiple patients with the alfapump demonstrate the benefits they see to their patients and how it fits into their clinical practice as well as the overall value delivered to the healthcare system in reducing hospital visits and enabling patients to focus on living rather than managing their condition.
“As we continue to engage with leading hospitals and advance our commercialisation strategy, we are thrilled to see the alfapump’s continued adoption by additional medical institutions to reach more patients across the US.”
